Published in Infect Immun on May 01, 1991
Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1 beta secretion from human monocytes. Infect Immun (1995) 1.86
Identification of App1 as a regulator of phagocytosis and virulence of Cryptococcus neoformans. J Clin Invest (2003) 1.66
Characterization of cellular infiltrates and cytokine production during the expression phase of the anticryptococcal delayed-type hypersensitivity response. Infect Immun (1993) 1.57
Capsular polysaccharide of Cryptococcus neoformans induces proinflammatory cytokine release by human neutrophils. Infect Immun (1996) 1.53
Phenotypic and functional characterization of human lymphocytes activated by interleukin-2 to directly inhibit growth of Cryptococcus neoformans in vitro. J Clin Invest (1993) 1.52
Direct interactions of human lymphocytes with the yeast-like organism, Cryptococcus neoformans. J Clin Invest (1993) 1.38
Encapsulation of Cryptococcus neoformans regulates fungicidal activity and the antigen presentation process in human alveolar macrophages. Clin Exp Immunol (1994) 1.37
Production and function of cytokines in natural and acquired immunity to Candida albicans infection. Microbiol Rev (1995) 1.32
Direct activity of human T lymphocytes and natural killer cells against Cryptococcus neoformans. Infect Immun (1994) 1.31
Antigen-induced protective and nonprotective cell-mediated immune components against Cryptococcus neoformans. Infect Immun (1998) 1.23
A 77-kilodalton protein of Cryptococcus neoformans, a member of the heat shock protein 70 family, is a major antigen detected in the sera of mice with pulmonary cryptococcosis. Infect Immun (1997) 1.14
Experimental model of intracerebral infection with Cryptococcus neoformans: roles of phagocytes and opsonization. Infect Immun (1992) 1.10
Differential host susceptibility to intracerebral infections with Candida albicans and Cryptococcus neoformans. Infect Immun (1993) 1.03
Regulation of cytokine production during the expression phase of the anticryptococcal delayed-type hypersensitivity response. Infect Immun (1994) 1.03
Enhanced resistance to Cryptococcus neoformans infection induced by chloroquine in a murine model of meningoencephalitis. Antimicrob Agents Chemother (1997) 1.01
Kinetics of cellular infiltration and cytokine production during the efferent phase of a delayed-type hypersensitivity reaction. Immunology (1997) 1.01
Direct interactions of human natural killer cells with Cryptococcus neoformans inhibit granulocyte-macrophage colony-stimulating factor and tumor necrosis factor alpha production. Infect Immun (1997) 0.99
Compartmentalization of innate immune responses in the central nervous system during cryptococcal meningitis/HIV coinfection. AIDS (2014) 0.98
Biomolecular events involved in anticryptococcal resistance in the brain. Infect Immun (1995) 0.97
Anticryptococcal resistance in the mouse brain: beneficial effects of local administration of heat-inactivated yeast cells. Infect Immun (1994) 0.92
A T cell-independent protective host response against Cryptococcus neoformans expressed at the primary site of infection in the lung. Infect Immun (1993) 0.91
Direct anticryptococcal activity of lymphocytes from Cryptococcus neoformans-immunized mice. Infect Immun (1995) 0.91
Effects of immunization with Cryptococcus neoformans cells or cryptococcal culture filtrate antigen on direct anticryptococcal activities of murine T lymphocytes. Infect Immun (1995) 0.89
Natural killer cells and antifungal host response. Clin Vaccine Immunol (2013) 0.88
CpG oligodeoxynucleotides promote the host protective response against infection with Cryptococcus neoformans through induction of interferon-gamma production by CD4+ T cells. Clin Exp Immunol (2005) 0.86
Leishmania-infected macrophages are targets of NK cell-derived cytokines but not of NK cell cytotoxicity. Infect Immun (2011) 0.84
Rapid microscopy and use of vital dyes: potential to determine viability of Cryptococcus neoformans in the clinical laboratory. PLoS One (2015) 0.83
Dysregulation in IL-12 secretion by neutrophils from HIV-infected patients. Clin Exp Immunol (2000) 0.81
Use of the tetrazolium salt MTT to measure cell viability effects of the bacterial antagonist Lysobacter enzymogenes on the filamentous fungus Cryphonectria parasitica. Antonie Van Leeuwenhoek (2013) 0.80
Requirement and redundancy of the Src family kinases Fyn and Lyn in perforin-dependent killing of Cryptococcus neoformans by NK cells. Infect Immun (2013) 0.79
History of medical mycology in the united states. Clin Microbiol Rev (1996) 0.78
Pulmonary Cryptococcosis in the Immunocompetent Patient-Many Questions, Some Answers. Open Forum Infect Dis (2016) 0.75
A rapid method for the isolation of functional thymus-derived murine lymphocytes. Eur J Immunol (1973) 45.44
Biology of natural killer cells. Adv Immunol (1989) 14.77
Estimation of bacterial densities by means of the "most probable number". Biometrics (1950) 10.81
Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique. Infect Immun (1972) 4.45
A rapid colorimetric assay of fungal viability with the tetrazolium salt MTT. J Infect Dis (1985) 3.58
In vitro reactivity of natural killer (NK) cells against Cryptococcus neoformans. J Immunol (1982) 2.19
A new fluorescent viability test for fungi cells. Mycopathologia (1979) 1.80
Morphological characterization of a cell population responsible for natural killer activity. Immunology (1981) 1.73
Mechanism of cytotoxicity by natural killer (NK) cells. Annu Rev Immunol (1986) 1.72
Recycling and target binding capacity of human natural killer cells. J Exp Med (1981) 1.71
Computation of most probable numbers. Appl Environ Microbiol (1983) 1.60
Natural cellular resistance of beige mice against Cryptococcus neoformans. J Immunol (1986) 1.44
Correlation of natural killer cell activity and clearance of Cryptococcus neoformans from mice after adoptive transfer of splenic nylon wool-nonadherent cells. Infect Immun (1986) 1.41
Role of natural killer cells in resistance to Cryptococcus neoformans infections in mice. Am J Pathol (1987) 1.34
In vitro binding of natural killer cells to Cryptococcus neoformans targets. Infect Immun (1985) 1.30
Mechanism of cell-mediated cytotoxicity at the single cell level. II. Evidence for first-order kinetics of T cell-mediated cytolysis and for heterogeneity of lytic rate. J Immunol (1979) 1.29
Murine natural killer cell interactions with a fungal target, Cryptococcus neoformans. Infect Immun (1989) 1.17
Injury and repair of yeasts and moulds. Soc Appl Bacteriol Symp Ser (1984) 1.16
Cytoplasmic components of natural killer cells limit the growth of Cryptococcus neoformans. J Leukoc Biol (1990) 1.01
Lethal and sublethal effects of refrigeration, freezing and freeze-drying on micro-organisms. Soc Appl Bacteriol Symp Ser (1984) 1.00
Binding interactions of murine natural killer cells with the fungal target Cryptococcus neoformans. Infect Immun (1991) 0.99
Evaluation of a fluorescent method (fluorescein diacetate and ethidium bromide solution) in the study of the viability Cryptococcus neoformans strains. Mycopathologia (1986) 0.86
B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell (1995) 6.88
Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc Natl Acad Sci U S A (1991) 4.48
Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique. Infect Immun (1972) 4.45
Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med (1995) 3.18
A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci U S A (1996) 3.07
A new member of the leucine zipper class of proteins that binds to the HLA DR alpha promoter. Science (1990) 2.83
Response of congenitally athymic (nude) and phenotypically normal mice to Cryptococcus neoformans infection. Infect Immun (1979) 2.76
Regulation of cell-mediated immunity in cryptococcosis. I. Induction of specific afferent T suppressor cells by cryptococcal antigen. J Immunol (1982) 2.36
Capsule size of Cryptococcus neoformans: control and relationship to virulence. Infect Immun (1977) 2.35
In vitro reactivity of natural killer (NK) cells against Cryptococcus neoformans. J Immunol (1982) 2.19
What makes Cryptococcus neoformans a pathogen? Emerg Infect Dis (1998) 2.18
Expression and functional significance of an additional ligand for CTLA-4. Proc Natl Acad Sci U S A (1993) 2.03
Early events in initiation of alternative complement pathway activation by the capsule of Cryptococcus neoformans. Infect Immun (1991) 1.90
Host-etiological agent interactions in intranasally and intraperitoneally induced Cryptococcosis in mice. Infect Immun (1980) 1.88
Transfer of immunity to cryptococcosis by T-enriched splenic lymphocytes from Cryptococcus neoformans-sensitized mice. Infect Immun (1980) 1.77
Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci U S A (1993) 1.72
WAG-F8(m1Ycb) rats harboring a factor VIII gene mutation provide a new animal model for hemophilia A. J Thromb Haemost (2010) 1.69
Cutting edge: Role of C-C chemokine receptor 5 in organ-specific and innate immunity to Cryptococcus neoformans. J Immunol (1999) 1.69
Antibody-dependent natural killer cell-mediated growth inhibition of Cryptococcus neoformans. Infect Immun (1986) 1.61
Characterization of cellular infiltrates and cytokine production during the expression phase of the anticryptococcal delayed-type hypersensitivity response. Infect Immun (1993) 1.57
Skin testing of guinea pigs and footpad testing of mice with a new antigen for detecting delayed hypersensitivity to Cryptococcus neoformans. Infect Immun (1974) 1.56
Regulation of cell-mediated immunity in cryptococcosis. II. Characterization of first-order T suppressor cells (Ts1) and induction of second-order suppressor cells. J Immunol (1983) 1.52
Stimulated renal tubular epithelial cells induce anergy in CD4+ T cells. Kidney Int (1993) 1.50
Regulation of cell-mediated immunity in cryptococcosis. III. Characterization of second-order T suppressor cells (Ts2). J Immunol (1985) 1.48
Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med (1995) 1.45
Natural cellular resistance of beige mice against Cryptococcus neoformans. J Immunol (1986) 1.44
Cloning of an interleukin-4 inducible gene from cytotoxic T lymphocytes and its identification as a lipase. Cell (1990) 1.44
Correlation of natural killer cell activity and clearance of Cryptococcus neoformans from mice after adoptive transfer of splenic nylon wool-nonadherent cells. Infect Immun (1986) 1.41
Intravascular cryptococcal culture filtrate (CneF) and its major component, glucuronoxylomannan, are potent inhibitors of leukocyte accumulation. Infect Immun (1995) 1.41
Cryptococcal polysaccharides bind to CD18 on human neutrophils. Infect Immun (1997) 1.41
Characterization of a third-order suppressor T cell (Ts3) induced by cryptococcal antigen(s). Infect Immun (1987) 1.39
Differential regulation of immune responses by highly and weakly virulent Cryptococcus neoformans isolates. Infect Immun (1999) 1.35
Uncompensated care by hospitals or public insurance for the poor. Does it make a difference? N Engl J Med (1986) 1.35
Effects of first-order Cryptococcus-specific T-suppressor cells on induction of cells responsible for delayed-type hypersensitivity. Infect Immun (1985) 1.34
Induction and expression of cell-mediated immune responses in inbred mice infected with Coccidioides immitis. Infect Immun (1988) 1.33
Cryptococcal culture filtrate antigen for detection of delayed-type hypersensitivity in cryptococcosis. Infect Immun (1979) 1.32
Effects of the two varieties of Cryptococcus neoformans cells and culture filtrate antigens on neutrophil locomotion. Infect Immun (1995) 1.31
In vitro binding of natural killer cells to Cryptococcus neoformans targets. Infect Immun (1985) 1.30
A child with partial deletion of a G-group autosome. Am J Dis Child (1967) 1.27
Selective CD28pYMNM mutations implicate phosphatidylinositol 3-kinase in CD86-CD28-mediated costimulation. Immunity (1995) 1.26
Structural mutation affecting intracellular transport and cell surface expression of murine class II molecules. J Exp Med (1988) 1.26
Cryptococcal polysaccharides induce L-selectin shedding and tumor necrosis factor receptor loss from the surface of human neutrophils. J Clin Invest (1996) 1.24
The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor. J Pharmacol Exp Ther (1999) 1.23
Enhanced MHC class II expression in renal proximal tubules precedes loss of renal function in MRL/lpr mice with lupus nephritis. Am J Pathol (1989) 1.17
Murine natural killer cell interactions with a fungal target, Cryptococcus neoformans. Infect Immun (1989) 1.17
Dendritic cells in the induction of protective and nonprotective anticryptococcal cell-mediated immune responses. J Immunol (2000) 1.16
Blockade of CD86 ameliorates Leishmania major infection by down-regulating the Th2 response. J Infect Dis (1996) 1.14
Mobility of human neutrophils in response to Cryptococcus neoformans cells, culture filtrate antigen, and individual components of the antigen. Infect Immun (1993) 1.11
Molecular cloning and expression of early T cell costimulatory molecule-1 and its characterization as B7-2 molecule. J Immunol (1994) 1.08
In vitro effects of natural killer cells against Paracoccidioides brasiliensis yeast phase. Infect Immun (1984) 1.07
Responses of murine natural killer cells to binding of the fungal target Cryptococcus neoformans. Infect Immun (1991) 1.06
Characterization of a cell population which amplifies the anticryptococcal delayed-type hypersensitivity response. Infect Immun (1990) 1.05
Antibody and/or cell-mediated immunity, protective mechanisms in fungal disease: an ongoing dilemma or an unnecessary dispute? Med Mycol (1998) 1.04
T cell response to soluble cryptococcal antigens after recovery from cryptococcal infection. J Infect Dis (1989) 1.04
Musculoskeletal responses to high- and low-intensity resistance training in early postmenopausal women. Med Sci Sports Exerc (2000) 1.03
In vitro induction of T cell anergy by blocking B7 and early T cell costimulatory molecule ETC-1/B7-2. Immunity (1994) 1.03
Immunoadsorption of Cryptococcus-specific suppressor T-cell factors. Infect Immun (1986) 1.03
Regulation of cytokine production during the expression phase of the anticryptococcal delayed-type hypersensitivity response. Infect Immun (1994) 1.03
A functional role for signal transduction via the cytoplasmic domains of MHC class II proteins. J Immunol (1989) 1.02
Cytoplasmic components of natural killer cells limit the growth of Cryptococcus neoformans. J Leukoc Biol (1990) 1.01
Kinetics of cellular infiltration and cytokine production during the efferent phase of a delayed-type hypersensitivity reaction. Immunology (1997) 1.01
Effects of cyclosporin A on the cells responsible for the anticryptococcal cell-mediated immune response and its regulation. Infect Immun (1989) 0.99
Binding interactions of murine natural killer cells with the fungal target Cryptococcus neoformans. Infect Immun (1991) 0.99
The Cryptococcus neoformans gene DHA1 encodes an antigen that elicits a delayed-type hypersensitivity reaction in immune mice. Infect Immun (2000) 0.99
MIP-1 alpha contributes to the anticryptococcal delayed-type hypersensitivity reaction and protection against Cryptococcus neoformans. J Leukoc Biol (1997) 0.98
Induction of antigen-specific T suppressor cells by soluble Paracoccidioides brasiliensis antigen. Infect Immun (1988) 0.98
Immunoglobulin isotype regulation by antigen-presenting cells in vivo. Eur J Immunol (1994) 0.97
Characterization of an in vitro-stimulated, Cryptococcus neoformans-specific second-order suppressor T cell and its precursor. Infect Immun (1988) 0.95
In vitro interactions of immune lymphocytes and Cryptococcus neoformans. Infect Immun (1982) 0.95
Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules. J Immunol (1996) 0.92
Direct antimicrobial activity of T cells. Immunol Today (1995) 0.92
Direct anticryptococcal activity of lymphocytes from Cryptococcus neoformans-immunized mice. Infect Immun (1995) 0.91
Expression and functional analysis of murine B7 delineated by a novel monoclonal antibody. Cell Immunol (1994) 0.91
Casein expression in cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1990) 0.91
Secretion of the C3 component of complement by peritoneal cells cultured with encapsulated Cryptococcus neoformans. Infect Immun (1997) 0.91
K562 cell strains differ in their response to poliovirus infection. Virology (1995) 0.91
Pathogenesis of Cryptococcus neoformans is associated with quantitative differences in multiple virulence factors. Mycopathologia (1999) 0.90
Monoclonal antibody 2D10 recognizes a novel T cell costimulatory molecule on activated murine B lymphocytes. J Immunol (1994) 0.90
CTLA-4 down-regulates the protective anticryptococcal cell-mediated immune response. Infect Immun (2000) 0.89
Effects of immunization with Cryptococcus neoformans cells or cryptococcal culture filtrate antigen on direct anticryptococcal activities of murine T lymphocytes. Infect Immun (1995) 0.89
Cytoplasmic domain affects membrane expression and function of an Ia molecule. Proc Natl Acad Sci U S A (1988) 0.89
Characterization of efferent T suppressor cells induced by Paracoccidioides brasiliensis-specific afferent T suppressor cells. Infect Immun (1988) 0.87
Differential induction of class II gene expression in murine pre-B-cell lines by B-cell stimulatory factor-1 and by antibodies to B-cell surface antigens. J Mol Cell Immunol (1988) 0.87
Effects of Cryptococcus neoformans-specific suppressor T cells on the amplified anticryptococcal delayed-type hypersensitivity response. Infect Immun (1991) 0.85
Intestinal secretion of digoxin in the rat. Augmentation by feeding activated charcoal. Naunyn Schmiedebergs Arch Pharmacol (1980) 0.85
Mechanisms for induction of L-selectin loss from T lymphocytes by a cryptococcal polysaccharide, glucuronoxylomannan. Infect Immun (1999) 0.84
Role of the C-C chemokine, TCA3, in the protective anticryptococcal cell-mediated immune response. J Immunol (1999) 0.84
Immunomodulation in the mycoses. J Med Vet Mycol (1992) 0.82
Intracardiac repair for anomalous pulmonary venous connection of right lung to inferior vena cava. Ann Thorac Surg (1971) 0.81
Mechanisms of cell-mediated immunity in fungal infection. J Med Vet Mycol (1994) 0.80
Deep seated giant arteriovenous malformations in infancy. Surg Neurol (1978) 0.77
IFN-gamma and b7 as costimulators of antitumor immune-responses. Int J Oncol (1995) 0.77
Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors. Eur J Immunol (1996) 0.77
Tolerability and anti-inflammatory effects of glucuronoxylomannan in collagen-induced arthritis. Scand J Immunol (2004) 0.77
Characterization of a sustained-release delivery system for combined cytokine/peptide vaccination using a poly-N-acetyl glucosamine-based polymer matrix. Clin Cancer Res (1997) 0.76